The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion

NCT02406443 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Sitaglitpin
OTHER: Placebo

Sponsor

University Health Network, Toronto

Collaborators

[object Object]